WO2000064930A3 - Tribonectins - Google Patents

Tribonectins Download PDF

Info

Publication number
WO2000064930A3
WO2000064930A3 PCT/US2000/010953 US0010953W WO0064930A3 WO 2000064930 A3 WO2000064930 A3 WO 2000064930A3 US 0010953 W US0010953 W US 0010953W WO 0064930 A3 WO0064930 A3 WO 0064930A3
Authority
WO
WIPO (PCT)
Prior art keywords
tribonectins
tribosupplementation
tribonectin
injured
administering
Prior art date
Application number
PCT/US2000/010953
Other languages
French (fr)
Other versions
WO2000064930A2 (en
Inventor
Gregory D Jay
Original Assignee
Rhode Island Hosp Lifespan Ptr
Gregory D Jay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23152784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000064930(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhode Island Hosp Lifespan Ptr, Gregory D Jay filed Critical Rhode Island Hosp Lifespan Ptr
Priority to CA2367750A priority Critical patent/CA2367750C/en
Priority to JP2000614279A priority patent/JP2003500022A/en
Priority to DE60041761T priority patent/DE60041761D1/en
Priority to AU44852/00A priority patent/AU781564B2/en
Priority to EP00926303A priority patent/EP1173567B2/en
Priority to ES00926303T priority patent/ES2324199T5/en
Publication of WO2000064930A2 publication Critical patent/WO2000064930A2/en
Publication of WO2000064930A3 publication Critical patent/WO2000064930A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Conductive Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)

Abstract

The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.
PCT/US2000/010953 1999-04-23 2000-04-24 Tribonectins WO2000064930A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2367750A CA2367750C (en) 1999-04-23 2000-04-24 Tribonectins
JP2000614279A JP2003500022A (en) 1999-04-23 2000-04-24 Tribonectin
DE60041761T DE60041761D1 (en) 1999-04-23 2000-04-24 TRIBONEKTINE
AU44852/00A AU781564B2 (en) 1999-04-23 2000-04-24 Tribonectins
EP00926303A EP1173567B2 (en) 1999-04-23 2000-04-24 Tribonectins
ES00926303T ES2324199T5 (en) 1999-04-23 2000-04-24 Tribonectins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/298,970 US6743774B1 (en) 1999-04-23 1999-04-23 Tribonectins
US09/298,970 1999-04-23

Publications (2)

Publication Number Publication Date
WO2000064930A2 WO2000064930A2 (en) 2000-11-02
WO2000064930A3 true WO2000064930A3 (en) 2001-01-25

Family

ID=23152784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010953 WO2000064930A2 (en) 1999-04-23 2000-04-24 Tribonectins

Country Status (9)

Country Link
US (6) US6743774B1 (en)
EP (1) EP1173567B2 (en)
JP (5) JP2003500022A (en)
AT (1) ATE425253T1 (en)
AU (1) AU781564B2 (en)
CA (1) CA2367750C (en)
DE (1) DE60041761D1 (en)
ES (1) ES2324199T5 (en)
WO (1) WO2000064930A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743774B1 (en) * 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
GB0003092D0 (en) 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
WO2001058958A1 (en) * 2000-02-09 2001-08-16 Glaxo Group Limited Antibody binding superficial zone protein and their uses in diagnosis and screening methods
WO2002062847A2 (en) * 2000-12-29 2002-08-15 Glaxo Group Limited Superficial zone protein and methods of making and using same
WO2002102403A1 (en) * 2001-06-14 2002-12-27 Novo Nordisk A/S Mucosal repair by tff dimer peptides
WO2005000331A2 (en) * 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
KR101078202B1 (en) * 2003-08-14 2011-11-01 와이어쓰 엘엘씨 Recombinant lubricin molecules and uses thereof
US20090155200A1 (en) * 2004-04-20 2009-06-18 Jay Gregory D Methods of promoting cartilage healing or cartilage integration
US20080287369A1 (en) * 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
US20080139458A1 (en) * 2004-12-03 2008-06-12 Jay Gregory D Methods of Treatment For Injured or Diseased Joints
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin
US20090298761A1 (en) * 2006-05-17 2009-12-03 Donald Engelman Methods of treating cartilage defects using a soluble morphogenic protein complex
US20090068247A1 (en) * 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US20090104148A1 (en) * 2007-09-18 2009-04-23 Jay Gregory D Treatment and prevention of joint disease
SI2285364T1 (en) 2008-05-07 2015-03-31 The Regents Of The University Of California Therapeutic replenishment and enrichment of ocular surface lubrication
ES2534082T3 (en) 2009-01-13 2015-04-17 Lubris Llc Therapeutic modulation of the lubrication of the vaginal epithelium boundary
WO2010087521A1 (en) * 2009-01-29 2010-08-05 独立行政法人理化学研究所 Combined preparation for treating joint diseases
CN102711796A (en) 2009-05-22 2012-10-03 卢布里斯有限责任公司 Application and uses of PRG4 and therapeutic modulation thereof
EP2525805B1 (en) 2010-01-19 2017-03-15 Lubris LLC Oral care compositions and methods
US8716204B2 (en) 2010-07-27 2014-05-06 Zimmer, Inc. Synthetic synovial fluid compositions and methods for making the same
US20130116186A1 (en) * 2011-10-04 2013-05-09 Rhode Island Hospital, A Lifespan Partner Lubricin injections to maintain cartilage health
EP2948553B1 (en) * 2013-01-25 2020-04-01 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
AU2014354859B2 (en) 2013-11-26 2020-04-09 Lubris Llc Compositions and methods for inhibiting intercellular interactions
RU2017129880A (en) 2015-01-26 2019-03-04 ЛУБРИС ЭлЭлСи APPLICATION OF PRG4 AS AN ANTI-INFLAMMATORY AGENT
US11666529B2 (en) 2015-05-19 2023-06-06 Lubris Llc Use of PRG4 to improve dynamic visual acuity and higher order aberrations
ES2835031T3 (en) * 2016-01-13 2021-06-21 Genzyme Corp Recombinant AAV vectors expressing osteoprotective genes, including HAS2 and lubricin, useful in the treatment of osteoarthritis and related joint conditions in mammals
US11137407B2 (en) 2016-02-23 2021-10-05 Lynxon Ab Method of diagnosing arthritis or other joint degrading disease
WO2021171165A1 (en) 2020-02-24 2021-09-02 Novartis Ag Purification of recombinantly produced polypeptides
JP7063369B2 (en) * 2020-12-07 2022-05-09 株式会社三洋物産 Pachinko machine
WO2023212598A1 (en) 2022-04-27 2023-11-02 Lubris Llc Methods of making polymer films

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013075A1 (en) * 1991-01-18 1992-08-06 Genetics Institute, Inc. Megakaryocyte stimulating factors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2734862A (en) 1956-02-14 Synthetic casein fiber elastic grease
US2487377A (en) 1948-04-17 1949-11-08 Socony Vacuum Oil Co Inc Lubricant
US2878184A (en) 1953-12-29 1959-03-17 Rockwell Mfg Co Hydrocarbon resistant glycerol base lubricant
AR207237A1 (en) 1974-02-25 1976-09-22 Thomas A PROCEDURE FOR OBTAINING SOLUBLE LYOPHILIZED STABLE BIOLOGICAL EXTRACTS CONSTITUTED BY THERMORE RESISTANT PROTEIN COMPLEXES
WO1981002977A1 (en) 1980-04-25 1981-10-29 Orthana Kemisk Fab As Sterilized,preserved,stable mucine-containing solutions and sterilization method
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
GB8803697D0 (en) 1988-02-17 1988-03-16 Deltanine Research Ltd Clinical developments using amniotic membrane cells
US5510418A (en) 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5260417A (en) 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
AU652022B2 (en) 1991-02-12 1994-08-11 C.R. Bard Inc. Injectable medical device
JPH04278061A (en) 1991-03-05 1992-10-02 Suntory Ltd Nutritious food
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5515590A (en) 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5709020A (en) 1994-07-19 1998-01-20 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5510122A (en) 1994-09-28 1996-04-23 The Research Foundation Of State University Of New York Preparation and use of whole saliva
FR2726188B1 (en) * 1994-11-02 1996-12-20 Inst Vaisseaux Et Du Sang GLYCOSAMINOGLYCAN / MEGACARYOCYTA GROWTH FACTOR COMPOSITION, USE IN THERAPEUTICS
US5639734A (en) * 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
AT405477B (en) * 1996-04-03 1999-08-25 Norbert Mag Fuchs COMBINATION PREPARATION
CA2270223A1 (en) 1996-10-28 1998-05-07 Carson B. Burgstiner (Deceased) Methods and compositions for dietary supplementation
US6960562B2 (en) * 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
US6743774B1 (en) * 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US7001881B1 (en) * 1999-04-23 2006-02-21 Rhode Island Hospital Tribonectins
JP2004517030A (en) * 1999-05-24 2004-06-10 アバロン バイオサイエンシーズ， インコーポレイテッド Glycosyltransferase inhibitors
AU6366100A (en) * 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents for the treatment of osteoarthritis
US6291533B1 (en) * 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
GB0003092D0 (en) * 2000-02-10 2000-03-29 Glaxo Group Ltd Superficial zone protein-binding molecules and uses thereof
WO2002062847A2 (en) * 2000-12-29 2002-08-15 Glaxo Group Limited Superficial zone protein and methods of making and using same
JP2005508297A (en) 2001-06-25 2005-03-31 インスパイアー ファーマシューティカルズ，インコーポレイティド Joint lubrication by P2Y purine receptor agonist
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US20030224386A1 (en) * 2001-12-19 2003-12-04 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
KR101078202B1 (en) 2003-08-14 2011-11-01 와이어쓰 엘엘씨 Recombinant lubricin molecules and uses thereof
EP1740190A1 (en) 2004-03-05 2007-01-10 Synthes GmbH Use of a mixture for the production of an agent for treating defective or degenerated cartilage in the production of natural cartilage replacement in vitro
US20080287369A1 (en) * 2004-07-23 2008-11-20 Jay Gregory D Compositions and Methods for Viscosupplementation
US20070111327A1 (en) * 2005-05-05 2007-05-17 Jay Gregory D Methods of detecting lubricin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013075A1 (en) * 1991-01-18 1992-08-06 Genetics Institute, Inc. Megakaryocyte stimulating factors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JAY ET AL.: "Comparison of the boundary-lubricating ability of bovine synovial fluid, lubricin and Healon", JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, vol. 40, no. 3, 5 June 1998 (1998-06-05), pages 414 - 418, XP000961337 *
JAY ET AL.: "Lubricin is a product of megaryocyte stimulating factor gene expression by human synovial fibroblasts", THE JOURNAL OF RHEUMATOLOGY, vol. 27, no. 3, March 2000 (2000-03-01), pages 594 - 600, XP000957779 *
MERBERG ET AL.: "Human megakyryocyte stimulating factor mRNA, complete cds", EMBL SEQUENCE DATABASE, 1 October 1996 (1996-10-01), HEIDELBERG DE, XP002152062 *
MERBERG ET AL.: "Megakaryocyte stimulating factor", EMBL SEQUENCE DATABASE, 1 February 1997 (1997-02-01), HEIDELBERG DE, XP002152061 *
PREISSNER ET AL. (EDS.): "Biology of vitronectins and their receptors", 1993, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, XP000961339 *
SCHUMACHER ET AL.: "Immunodetection and partial cDNA sequence of the proteoglycan, superficial zone protein, synthesized by cells lining synovial joints", JOURNAL OF ORTHOPAEDIC RESEARCH, vol. 17, no. 1, 1 January 1999 (1999-01-01), pages 110 - 120, XP000961311 *

Also Published As

Publication number Publication date
EP1173567B1 (en) 2009-03-11
AU4485200A (en) 2000-11-10
US20140179611A1 (en) 2014-06-26
CA2367750A1 (en) 2000-11-02
ATE425253T1 (en) 2009-03-15
AU781564B2 (en) 2005-06-02
EP1173567A2 (en) 2002-01-23
US20040229804A1 (en) 2004-11-18
US20100048458A1 (en) 2010-02-25
ES2324199T5 (en) 2013-03-20
JP5909592B2 (en) 2016-04-26
ES2324199T3 (en) 2009-08-03
US7618941B2 (en) 2009-11-17
CA2367750C (en) 2013-10-22
JP2012070738A (en) 2012-04-12
US6743774B1 (en) 2004-06-01
US8680057B2 (en) 2014-03-25
JP2016041769A (en) 2016-03-31
WO2000064930A2 (en) 2000-11-02
EP1173567B2 (en) 2012-10-31
JP2014144015A (en) 2014-08-14
JP2016172760A (en) 2016-09-29
US8026346B2 (en) 2011-09-27
JP2003500022A (en) 2003-01-07
US20100204087A1 (en) 2010-08-12
US20130072435A1 (en) 2013-03-21
DE60041761D1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
WO2000064930A3 (en) Tribonectins
AU4978400A (en) Methods of sealing an injection site
AU2180400A (en) A pharmaceutical combination for the treatment of depression
AU2002241534A1 (en) Disposable aerosol generator system and methods for administering the aerosol
AU7382000A (en) Composite joint configuration
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
PT1465693E (en) Disposable aerosol generator system and methods for administering the aerosol
AU4363300A (en) Ultrasound for autocapture or other applications
HK1027280A1 (en) Plant extracts for the treatment of increased boneresorption.
AU3198699A (en) Method for the treatment of joint diseases characterized by unwanted pannus
WO2001010816A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
AU2003258145A1 (en) Substituted phenylindoles for the treatment of hiv
WO1999032509A3 (en) Hemiasterlin analogs
AU2035401A (en) Lubricant combination and process for the preparation thereof
AU5038299A (en) Process for the biocidal treatment of surfaces
WO2003043546A3 (en) Joint prosthesis
AU7465400A (en) Lubricant composite and process for the preparation thereof
AU7750100A (en) Method for the treatment of obesity
WO2000042987A8 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
AU2001274601A1 (en) Preventives or remedies for heart failure
HK1040234A1 (en) Joining method for ceramics and metal and joined body of ceramics and metal joined by the method.
AU7773700A (en) Method for the production or preparation of 2,6-dichlorotoluol
AU4751300A (en) Method and device for the continuous production of NaAlCl4 or NaFeCl4
AU6489499A (en) Device for restoring the mobility of joints
AU4107100A (en) Method of producing composites, composites and the use of such composites

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 614279

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2367750

Country of ref document: CA

Ref country code: CA

Ref document number: 2367750

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000926303

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000926303

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642